The test could pick up on the very early stages of Alzheimer's disease with 100 per cent accuracy when tested on 174 individuals.
The blood test could be used to spot which patients are most at risk so that treatment can begin earlier or lifestyles altered, Telegraph reported.
"We will need replication and validation, but I'm very optimistic this work will hold," said Dimitrios Kapogiannis, the study's lead author and a neuroscientist at the National Institute on Ageing.
Of the participants, 22 of the Alzheimer's patients provided samples taken one to 10 years before diagnosis.
Researchers found that those participants who went on to get Alzheimer's had far higher levels of the inactive form of IRS-1.
These levels were so consistent that the team could accurately predict whether a blood sample came from an Alzheimer's patient, healthy individual, or a diabetic.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
